Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Glioblastoma 94Glioma 32Brain Neoplasms 29Melanoma 21Neoplasms 17Astrocytoma 17Sarcoma, Ewing 7Ovarian Neoplasms 7Gliosarcoma 7Carcinoma, Non-Small-Cell Lung 7Neuroblastoma 6Neoplasm Metastasis 6Medulloblastoma 6Breast Neoplasms 6Sarcoma 5Recurrence 5Diffuse Intrinsic Pontine Glioma 5Small Cell Lung Carcinoma 4Rhabdomyosarcoma 4Oligodendroglioma 4Spinal Cord Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Central Nervous System Neoplasms 3Triple Negative Breast Neoplasms 2Rhabdoid Tumor 2Neuroendocrine Tumors 2Lymphoma, Follicular 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2

Interventions

pembrolizumab 1Temozolomide 1Paclitaxel 1Dacarbazine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Melanoma × Temozolomide × Clear all
NCT07310784 2026-05-12

A Phase II Trial of LM103 in Advanced Melanoma

Suzhou BlueHorse Therapeutics Co., Ltd.

Phase 2 Recruiting
92 enrolled
Dermatologic

Advanced Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡